Collegium Pays $17M to Settle Nucynta Patent Suit and End Grünenthal Royalties
COLL is trading near its 52-week low of $21.43 (7.4% above the low).
Summary
Collegium will pay Grünenthal $17 million to settle the Nucynta patent lawsuit and terminate the related license. The deal eliminates all future royalties on the product and transfers certain Nucynta patents to Collegium.
Key Events · Legal and Risk Events · COLL
-
Nucynta Litigation Settled for $17M
Collegium and Grünenthal entered a settlement agreement on October 15, 2026 resolving the patent infringement suit Grünenthal filed in February 2026 over the Nucynta ER authorized generic.
-
License Terminated, Royalties Eliminated
The Grünenthal License and the Consent Agreement (as to the Territory) terminate effective October 15, 2026 upon Collegium's $17,000,000 payment. All royalty obligations are fully discharged with no further royalties due.
-
Nucynta Patents Assigned to Collegium
Grünenthal assigned certain Nucynta-related patents to Collegium and moved to dismiss the litigation as part of the settlement.
-
One-Time $17M Cash Outlay
The $17 million payment is a discrete cash cost; the benefit is the permanent removal of Nucynta royalty expense from the P&L going forward.
Analysis · COLL · Life Sciences
Why it matters: Collegium is paying $17 million to Grünenthal to end both the Nucynta patent litigation and the underlying license. The cash cost is real but bounded, and it buys something more valuable. The royalty stream on Nucynta is gone for good, and Collegium now owns certain Nucynta patents outright. That permanently lowers the cost of selling its largest legacy product line and removes a legal overhang that has hung over the franchise since the February 2026 complaint. Against a $749M market cap, $17M is a manageable one-time hit for cleaner, higher-margin Nucynta economics going forward.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, COLL was trading at $23.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $749.1M. The 52-week trading range was $21.43 to $50.79. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.